Last reviewed · How we verify
Lisurid (LISURIDE)
Lisurid (generic name: LISURIDE) is a lisuride drug. It is currently in Phase 3 development for Acromegaly, Amenorrhea, Migraine.
Lisuride works by binding to and activating the alpha-2A adrenergic receptor, which helps to regulate various physiological processes.
Lisuride is a small molecule used in the treatment of various conditions, including Parkinson's Disease and Restless Legs Syndrome, through different administration methods such as intravenous and transdermal systems. It has been studied in clinical trials for its potential therapeutic effects on these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LISURIDE |
|---|---|
| Drug class | lisuride |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 3 |
Mechanism of action
Imagine your body has a 'brake' system that helps to slow down certain processes. Lisuride works by pressing this brake, which can help to reduce symptoms of conditions like Migraine and Acromegaly. This is achieved by influencing the release of certain neurotransmitters and hormones.
Approved indications
- Acromegaly
- Amenorrhea
- Migraine
Common side effects
Key clinical trials
- Lisuride Patch to Treat Parkinson's Disease (PHASE2)
- Infusion Laboratory: Protocol 2 (Lisuride) - 3 (PHASE1)
- MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (PHASE3)
- Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) (PHASE3)
- Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lisurid CI brief — competitive landscape report
- Lisurid updates RSS · CI watch RSS
Frequently asked questions about Lisurid
What is Lisurid?
How does Lisurid work?
What is Lisurid used for?
What is the generic name of Lisurid?
What drug class is Lisurid in?
What development phase is Lisurid in?
What does Lisurid target?
Related
- Drug class: All lisuride drugs
- Target: All drugs targeting Alpha-2A adrenergic receptor
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Acromegaly
- Indication: Drugs for Amenorrhea
- Indication: Drugs for Migraine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing